Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Heterocyclic derivatives
4571394 Heterocyclic derivatives
Patent Drawings:

Inventor: Hayes, et al.
Date Issued: February 18, 1986
Application: 06/401,402
Filed: July 23, 1982
Inventors: Bays; David E. (Hertfordshire, GB)
Hayes; Roger (Hertfordshire, GB)
MacKinnon; John W. M. (Hertfordshire, GB)
Assignee: Glaxo Group Limited (London, GB2)
Primary Examiner: Gerstl; Robert
Assistant Examiner:
Attorney Or Agent: Bacon & Thomas
U.S. Class: 514/217.06; 514/217.09; 514/230.8; 514/235.8; 514/236.2; 514/239.5; 514/326; 514/340; 514/383; 540/603; 544/132; 546/272.4; 548/262.8; 548/263.8; 548/264.8; 548/265.2
Field Of Search: 548/264; 548/265; 548/266; 546/210; 546/276; 544/132; 260/245.5; 514/383; 514/326; 514/237; 514/212; 514/340
International Class:
U.S Patent Documents: 4410523; 4411899
Foreign Patent Documents:
Other References:









Abstract: The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in whichQ represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4- positions:Z represents one of the groups ##STR2## where X represents NCN, NSO.sub.2 Methyl, NSO.sub.2 Phenyl or CHNO.sub.2. The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.
Claim: We claim:

1. A compound of the formula (I) ##STR33## and physiologically acceptable salts and hydrates thereof, in which R.sub.1 represents hydrogen, C.sub.1-14 alkyl, C.sub.3-8 cycloalkyl,C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, ar C.sub.1-6 alkyl, trifluoro C.sub.1-6 alkyl, heteroaralkyl, or C.sub.1-6 alkyl substituted by C.sub.3-8 cycloalkyl, hydroxy, C.sub.1-6 alkoxy, amino, C.sub.1-6 alkylamino or di C.sub.1-6 alkylamino;

R.sub.2 represents hydrogen or a C.sub.1-4 alkyl group;

or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached, form piperidino, morpholino, 4-methylpiperidino, pyrrolidino, hexamethyleneimino or tetrahydropyridino;

Alk represents a straight or branched alkylene chain of 1 to 3 carbon atoms;

Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4-positions;

R.sub.5 represents hydrogen or C.sub.1-4 alkanoyl;

n and m which may be the same or different, are each 1 or 2;

Z represents ##STR34## wherein R.sub.3 represents C.sub.1-6 alkyl, C.sub.3-6 alkenyl, ar C.sub.1-6 alkyl, hydroxy C.sub.2-6 alkyl, C.sub.1-6 alkoxy C.sub.2-6 alkyl or C.sub.1-4 alkanoyloxy C.sub.2-6 alkyl;

R.sub.7 represents hydrogen, C.sub.1-6 alkyl, C.sub.3-6 alkenyl, ar C.sub.1-6 alkyl, acyloxy C.sub.1-6 alkyl, C.sub.1-6 alkylthio C.sub.1-6 alkyl, arylthio C.sub.1-6 alkyl, aryloxy C.sub.1-6 alkyl, ar C.sub.1-6 alkyloxy C.sub.1-6 alkyl, or thegroup (CH.sub.2).sub.q R.sub.6 where q is zero, 1, 2, 3, 4, 5 or 6 and the alkylene chain (CH.sub.2).sub.q may be straight or branched, and

R.sub.6 is hydroxy, C.sub.1-6 alkoxy, nitro, heteroaryl, tetrahydropyranyloxy, CH.sub.2 NHC(.dbd.X)NHR.sub.9 wherein X represents NCN, NSO.sub.2 methyl, NSO.sub.2 phenyl or CHNO.sub.2 ; and R.sub.9 is C.sub.1-6 alkyl;

or R.sub.6 is the group NR.sub.10 R.sub.11, where R.sub.10 is hydrogen or alkyl; and R.sub.11 is hydrogen, alkyl, alkenyl, aryl, aralkyl, or heteroaralkyl, or R.sub.11 is the group SO.sub.2 R.sub.12 where R.sub.12 is alkyl or aryl; or R.sub.11is the group COR.sub.13 where R.sub.13 is hydrogen, alkyl, aryl, aralkyl, alkoxy, halomethyl, heteroaryl, heteroaralkyl or the group NHR.sub.14 where R.sub.14 is hydrogen, alkyl, cycloalkyl, aryl or aralkyl; or R.sub.10 and R.sub.11 together representthe group .dbd.CR.sub.15 R.sub.16 where R.sub.15 represents aryl or heteroaryl and R.sub.16 represents hydrogen or alkyl;

or R.sub.6 is the group SO.sub.2 R.sub.17 in which R.sub.17 is hydroxy, alkyl, aryl or the group NR.sub.18 R.sub.19 where R.sub.18 and R.sub.19, which may be the same or different, each represents hydrogen or alkyl;

or R.sub.6 is the group COR.sub.20 where R.sub.20 is hydrogen, hydroxy, alkoxy, aryloxy, aralkyloxy, alkyl, aryl, aralkyl or the group NR.sub.21 R.sub.22 where R.sub.21 is hydrogen, alkyl, or alkyl substituted by a hydroxy or alkoxy group; andR.sub.22 is hydrogen, alkyl, or alkyl substituted by a hydroxy or alkoxy group, alkenyl, aryl, aralkyl or cycloalkyl, or NR.sub.21 R.sub.22 forms a 5 to 8 membered ring which may contain oxygen, or a double bond and/or may be substituted by hydroxy orone or two C.sub.1-3 alkyl groups; or R.sub.6 is the group CR.sub.23 .dbd.NR.sub.24 where R.sub.23 is hydrogen, alkyl, aryl or aralkyl and R.sub.24 is hydroxy, alkoxy, aralkyloxy or --NHC(.dbd.Y)NH.sub.2 where Y is oxygen or suplhur;

with the proviso that when the group R.sub.6 contains a carbon atom through which it is linked to the alkylene group (CH.sub.2).sub.q then the total number of carbon atoms in the resulting chain is not greater than 6;

wherein unless specifically defined hereinbefore, alkyl as a group or part of a group, represents a straight chain C.sub.1-6 alkyl group or a branched chain C.sub.1-6 alkyl group, alkenyl represents a C.sub.3-6 alkenyl group; alkynyl representsa C.sub.3-6 alkynyl group; cycloalkyl represents a C.sub.3-8 cycloalkyl group; halomethyl represents a mono-, di- or trihalo substituted methyl group; aryl as a group or part of a group represents phenyl or phenyl substituted with one or moreC.sub.1-3 alkyl or alkoxy groups or halogen atoms; the acyl portion of an acyloxyalkyl group represents an aroyl group, an aralkanoyl group or C.sub.1-6 alkanoyl group; heteroaryl as a group or part of a group represents a 5 or 6 membered monocyclicring containing from 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur; and the heteroaryl ring may be unsubstituted or substituted by C.sub.1-3 alkyl, C.sub.1-3 alkoxy, hydroxy C.sub.1-6 alkyl, amino C.sub.1-6 alkyl, C.sub.1-6 alkylaminoC.sub.1-6 alkyl, di C.sub.1-6 alkylamino C.sub.1-6 alkyl or halogen; and the alkyl portion of a heteroaralkyl group is a straight or branched C.sub.1-4 alkyl chain, and the heteroaryl ring is linked to the alkyl portion through a carbon atom.

2. A compound as claimed in claim 1 in which

R.sub.1 represents C.sub.1-8 alkyl, C.sub.1-4 alkyl substituted by a trifluoromethyl group, C.sub.2-4 alkyl substituted by hydroxy or a di C.sub.1-3 alkylamino group, C.sub.5-7 cycloalkyl, C.sub.3-5 alkenyl, phenyl C.sub.1-3 alkyl, or aheteroaryl C.sub.1-3 alkyl group where the heteroaryl ring contains one heteroatom;

R.sub.2 represents hydrogen or methyl; or

R.sub.1 R.sub.2 N represents a 5 to 7 membered ring optionally containing a double bond, an oxygen atom or an alkyl substituent;

Alk represents methylene;

R.sub.3 represents alkyl, or hydroxy C.sub.2-4 alkyl;

Q represents a benzene ring incorporated into the rest of the molecule through bonds at the 1- and 3-positions;

R.sub.5 represents hydrogen or alkanoyl;

n and m both represent 1, or one of n and m represents 2;

R.sub.7 represents alkoxyalkyl, alkylthioalkyl, alkanoyloxyalkyl, benzyl, or --CH.dbd.NOH;

or R.sub.7 represents the group (CH.sub.2).sub.q R.sub.6 where q is zero, 1, 2 or 3, and R.sub.6 represents hydroxyl, CH.sub.2 NHSO.sub.2 R.sub.12 (where R.sub.12 is alkyl), CH.sub.2 NHC(.dbd.X)NHCH.sub.3 (where X.dbd.NCN or CHNO.sub.2), SO.sub.2R.sub.17 (where R.sub.17 is alkyl), or R.sub.6 represents COR.sub.20 where R.sub.20 is hydroxyl or NR.sub.21 R.sub.22 and R.sub.21 and R.sub.22 independently represent hydrogen or C.sub.1-3 alkyl or R.sub.21 and R.sub.22 together with the nitrogen atomto which they are attached represent a pyrrolidino ring, or

R.sub.6 represents the group NR.sub.10 R.sub.11 where R.sub.10 represents hydrogen and R.sub.11 is hydrogen or COR.sub.13, where R.sub.13 represents hydrogen, alkyl, phenyl, benzyl, alkoxy, NH phenyl, or R.sub.10 and R.sub.11 together representthe group .dbd.CHR.sub.15 where R.sub.15 is phenyl or pyridyl;

R.sub.4 represents pyridinyl optionally substituted by an alkyl group; or a phenyl group optionally substituted by an alkoxy group;

p represents 1;

R.sub.8 represents alkyl;

X represents CHNO.sub.2.

3. A compound as claimed in claim 1 of formula (II) ##STR35## in which R.sub.1 R.sub.2 N is dimethylamino, pyrrolidino, piperidino or hexamethylenimino; and Z represents ##STR36## where R.sub.3 is methyl and R.sub.7 is hydroxymethyl, amino,alkanoyloxyalkyl, N.dbd.CHPh, (CH.sub.2).sub.3 NHC(.dbd.CHNO.sub.2)NHMe, aminopropyl, methylsulphonylmethyl or acetylamino.

4. A compound as claimed in claim 1 wherein R.sub.5 is hydrogen or acetyl.

5. A compound as claimed in claim 1 wherein heteroaryl as a group or part of a group is an unsubstituted thienyl, pyrrolyl, pyridyl, furyl or a thiazolyl group or such a group substituted by C.sub.1-3 alkyl, C.sub.1-3 alkoxy, hydroxy C.sub.1-6alkyl, amino-C.sub.1-6 alkyl or diC.sub.1-6 alkylamino C.sub.1-6 alkyl.

6. A compound as claimed in claim 1, wherein R.sub.5 is hydrogen.

7. 1-[(3-Amino-1-methyl-1H-1,2,4-triazol-5-yl)amino]-3-[3-(1-pipe ridinylmethyl)phenoxy]-2-propanol; 5-[[2-hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-1-methyl-1H- 1,2,4-triazole-3-methanol; 2-[[2-hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-5-[(6-methyl -3-pyridinyl)methyl]-4-(3H)-pyrimidinone; 2-[[2-hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-5-(3-pyridin ylmethyl)-4(3H)-pyrimidinone; 2-[[2-hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-5-[(4-methox yphenyl)methyl]-4-(3H)-pyrimidinone; or a physiologically acceptable salt thereof.

8. A pharmaceutical composition for the treatment of conditions mediated through histamine H.sub.2 -receptors which comprises an effective amount to relieve said condition of a compound as claimed in claim 1 together with at least one inertpharmaceutically acceptable carrier or diluent.

9. A method of treating a condition mediated through histamine H.sub.2 -receptors which comprises administering to a patient an effective amount of compound as claimed in claim 1 to relieve said condition.
Description: This invention relates to novel heterocyclic derivatives having action on histamine receptors, to processes for the preparation thereof, to pharmaceutical compositions containing them and to their use intherapeutics.

Certain novel heterocyclic derivatives have now been found which have potent activity as H.sub.2 -antagonists. These compounds, which are more particularly described below, for example show inhibition of the secretion of gastric acid when thisis stimulated via histamine receptors (Ash and Schild, Brit. J. Pharmacol. Chemother, 1966, 27, 427). Their ability to do so can be demonstrated in the perfused rat stomach using the method described in British Patent Specification Number 1665966,modified by the use of sodium pentobarbitone (50 mg/kg) as anaesthetic instead of urethane, and in conscious dogs equipped with Heidenhain pouches using the method described by Black et al, Nature 1972 236, 385. Furthermore, the compounds antagonise theeffect of histamine on the contraction frequency of isolated guinea pig right atrium.

Compounds with histamine H.sub.2 -blocking activity may be used in the treatment of conditions where there is an advantage in lowering gastric acidity, particularly in gastric and peptic ulceration, as a prophylactic measure in surgicalprocedures, and in the treatment of allergic and inflammatory condition, where histamine is a known mediator. Thus they may be used for example, either alone or in combination with other active ingredients in the treatment of allergic and inflammatoryconditions of the skin.

The present invention provides compounds of the general formula (I): ##STR3## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which

R.sub.1 represents hydrogen, C.sub.1-14 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl, heteroaralkyl or alkyl substituted by cycloalkyl, hydroxy, alkoxy, amino, alkylamino or dialkylamino; and

R.sub.2 represents hydrogen or C.sub.1-4 alkyl group; or

R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a 5 to 10 membered ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C.sub.1-3 alkylgroups, e.g. methyl, or a hydroxy group and/or may contain another heteroatom selected from oxygen or sulphur;

Alk represents a straight or branched alkylene chain of 1 to 3 carbon atoms;

Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4-positions;

R.sub.5 represents hydrogen or acyl;

n and m, which may be the same or different, are each 1 or 2;

Z represents one of the groups ##STR4## where

X represents NCN, NSO.sub.2 Methyl, NSO.sub.2 Phenyl or CHNO.sub.2 ;

R.sub.8 represents alkyl;

R.sub.3 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxy C.sub.2-6 alkyl, alkoxy C.sub.2-6 alkyl or C.sub.1-4 alkanoyloxy-C.sub.2-6 alkyl;

R.sub.7 represents hydrogen, alkyl, alkenyl, aralkyl, acyloxyalkyl, alkylthioalkyl, arylthioalkyl, aryloxyalkyl, aralkyloxyalkyl, or the group (CH.sub.2).sub.q R.sub.6 where q is zero, 1, 2, 3, 4, 5 or 6 and the alkylene chain (CH.sub.2).sub.qmay be straight or branched, and

R.sub.6 is hydroxy, alkoxy, nitro, heteroaryl, tetrahydropyranyloxy or CH.sub.2 NHC(.dbd.X)NHR.sub.9 where X is as defined above and R.sub.9 is alkyl;

or R.sub.6 is the group NR.sub.10 R.sub.11 where R.sub.10 is hydrogen or alkyl; and R.sub.11 is hydrogen, alkyl, alkenyl, aryl, aralkyl, or heteroaralkyl, or R.sub.11 is the group SO.sub.2 R.sub.12 where R.sub.12 is alkyl or aryl; or R.sub.11 isthe group COR.sub.13 where R.sub.13 is hydrogen, alkyl, aryl, aralkyl, alkoxy, halomethyl, heteroaryl, heteroaralkyl or the group NHR.sub.14 where R.sub.14 is hydrogen, alkyl, cycloalkyl, aryl or aralkyl; or R.sub.10 and R.sub.11 together represent thegroup .dbd.CR.sub.15 R.sub.16 where R.sub.15 represents aryl or heteroaryl and R.sub.16 represents hydrogen or alkyl;

or R.sub.6 is the group SO.sub.2 R.sub.17 in which R.sub.17 is hydroxy, alkyl, aryl or the group NR.sub.18 R.sub.19 where R.sub.18 and R.sub.19, which may be the same or different, each represent hydrogen or alkyl;

or R.sub.6 is the group COR.sub.20 where R.sub.20 is hydrogen, hydroxy, alkoxy, aryloxy, aralkyloxy, alkyl, aryl, aralkyl or the group NR.sub.21 R.sub.22 where R.sub.21 is hydrogen or alkyl optionally substituted by a hydroxy or alkoxy group; andR.sub.22 is hydrogen, alkyl (optionally substituted by a hydroxy or alkoxy group), alkenyl, aryl, aralkyl or cycloalkyl, or NR.sub.21 R.sub.22 forms a 5 to 8 membered ring which may contain another heteroatom, e.g. oxygen, or a double bond and/or may besubstituted by hydroxy or one or two C.sub.1-3 alkyl (e.g. methyl) groups; or R.sub.6 is the group CR.sub.23 .dbd.NR.sub.24 where R.sub.23 is hydrogen, alkyl, aryl or aralkyl and R.sub.24 is hydroxy, alkoxy, aralkyloxy or --NHC(.dbd.Y)NH.sub.2 where Y isoxygen or sulphur;

with the proviso that when the group R.sub.6 contains a carbon atom through which it is linked to the alkylene group (CH.sub.2).sub.q then the total number of carbon atoms in the resulting chain is not greater than 6 (i.e. q is not greater than5);

R.sub.4 represents phenyl, phenoxy or pyridinyl which may optionally be substituted by one or more halogen, alkyl, alkoxyalkyl or alkoxy groups or by a methylenedioxy group;

p represents an integer which is 1, 2 or 3.

The term "alkyl" as a group or part of a group means that the group is straight or branched, and unless otherwise stated, has preferably 1 to 6 carbon atoms and in particular 1 to 4 carbon atoms, e.g. methyl or ethyl; and the terms "alkenyl" and"alkynyl" mean that the groups preferably contain 3 to 6 carbon atoms. The term "cycloalkyl" means that the group has 3 to 8 carbon atoms. The term "halomethyl" means a mono-, di- or trihalo substituted methyl group, e.g. trifluoromethyl. The term"aryl" as a group or part of a group preferably means phenyl or substituted phenyl, for example phenyl substituted with one or more C.sub.1-3 alkyl or alkoxy groups or halogen atoms, e.g. fluorine. The term acyl or the acyl portion of an acyloxyalkylgroup means an aroyl, aralkanoyl or C.sub.1-6 alkanoyl group. Examples of acyloxyalkyl groups include acetoxymethyl, formyloxymethyl, benzoyloxymethyl and phenylacetoxymethyl. The term heteroaryl as a group or part of a group means a 5 or 6 memberedmonocyclic ring containing from 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, e.g. thienyl, pyrrolyl, pyridyl, furyl or thiazolyl. The heteroaryl ring may be unsubstituted or substituted by C.sub.1-3 alkyl, C.sub.1-3 alkoxy,hydroxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl or halogen, for example, the heteroaryl ring may be thienyl or furyl substituted by C.sub.1-3 alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl or hydroxyalkyl, pyrrolyl substituted byC.sub.1-3 alkyl, pyridyl substituted by C.sub.1-3 alkyl, C.sub.1-3 alkoxy, halogen or hydroxyalkyl or thiazolyl substituted by C.sub.1-3 alkyl or hydroxyalkyl. The alkyl portion of a heteroaralkyl group is a straight or branched C.sub.1-4 alkyl chain,and the heteroaryl ring is linked to the alkyl portion through a carbon atom.

According to one aspect the invention provides compounds of formula (I) in which Z is ##STR5##

R.sub.5 represents hydrogen or a C.sub.1-4 alkanoyl group;

R.sub.3 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxy C.sub.2-6 alkyl, or alkoxy C.sub.2-6 alkyl;

R.sub.7 is as defined in formula (I) except that R.sub.6 does not represent tetrahydropyranyloxy; and

R.sub.1, R.sub.2, Alk, Q, n and m are as defined in formula (I).

According to another aspect the invention provides compounds of formula (I) in which Z is ##STR6##

R.sub.5 represents hydrogen or a C.sub.1-4 alkanoyl group; and

R.sub.1, R.sub.2, R.sub.4, Alk, Q, m, n and p are as defined in formula (I).

Preferred compounds of formula (I) are those in which

R.sub.1 represents C.sub.1-8 alkyl (e.g. methyl, propyl, butyl or heptyl), C.sub.1-4 alkyl substituted by a trifluoromethyl group (e.g. 2,2,2-trifluoroethyl), C.sub.2-4 alkyl substituted by hydroxy or a di C.sub.1-3 alkylamino group (e.g.3-hydroxypropyl or dimethylaminoethyl), C.sub.5-7 cycloalkyl (e.g. cyclohexyl), C.sub.3-5 alkenyl (e.g. allyl), phenyl C.sub.1-3 alkyl (e.g. benzyl), or a heteroaryl C.sub.1-3 alkyl group where the heteroaryl ring contains one heteroatom (e.g.2-furylmethyl);

R.sub.2 represents hydrogen or methyl; or

R.sub.1 R.sub.2 N represents a 5 to 7 membered ring optionally containing a double bond, an oxygen atom or an alkyl (e.g. methyl) substituent (e.g. piperidino, morpholino, 4-methylpiperidino, pyrrolidino, hexamethylenimino or tetrahydropyridino);

Alk represents methylene;

R.sub.3 represents hydrogen, alkyl (e.g. methyl or ethyl), hydroxy C.sub.2-4 alkyl (e.g. hydroxyethyl);

Q represents a benzene ring incorporated into the rest of the molecule through bonds at the 1- and 3-positions;

R.sub.5 represents hydrogen or alkanoyl (e.g. acetyl);

n and m both represent 1 or one of n and m represents 2;

R.sub.7 represents alkoxyalkyl, alkylthioalkyl, alkanoyloxyalkyl, benzyl, or --CH.dbd.NOH;

or R.sub.7 represents the group (CH.sub.2).sub.q R.sub.6 where q is zero, 1, 2 or 3, and R.sub.6 represents hydroxyl, CH.sub.2 NHSO.sub.2 R.sub.12 (where R.sub.12 is alkyl), CH.sub.2 NHC(.dbd.X)NHCH.sub.3 (where X.dbd.NCN or CHNO.sub.2), SO.sub.2R.sub.17 (where R.sub.17 is alkyl), or R.sub.6 represents COR.sub.20 where R.sub.20 is hydroxyl or NR.sub.21 R.sub.22 and R.sub.21 and R.sub.22 independently represent hydrogen or C.sub.1-3 alkyl or R.sub.21 and R.sub.22 together with the nitrogen atomto which they are attached represent a pyrrolidino ring, or

R.sub.6 represents the group NR.sub.10 R.sub.11 where R.sub.10 represents hydrogen and R.sub.11 is hydrogen or COR.sub.13, where R.sub.13 represents hydrogen, alkyl, phenyl, benzyl, alkoxy, NH phenyl, or R.sub.10 and R.sub.11 together representthe group .dbd.CHR.sub.15 where R.sub.15 is phenyl or pyridyl;

R.sub.4 represents pyridinyl (e.g. 3-pyridinyl) optionally substituted by an alkyl (e.g. methyl) group; or a phenyl group optionally substituted by an alkoxy (e.g. methoxy) group;

p represents 1;

R.sub.8 represents alkyl (e.g. methyl);

X represents CHNO.sub.2.

A further preferred class of compounds of formula (I) are those of formula (II) ##STR7## in which R.sub.1 R.sub.2 N is dimethylamino, pyrrolidino, piperidino or hexamethylenimino, more preferably piperidino and Z represents ##STR8## where R.sub.3is hydrogen or methyl and R.sub.7 is hydroxymethyl, amino, alkanoyloxyalkyl (preferably acetoxymethyl), N.dbd.CHPh, (CH.sub.2).sub.3 NHC(.dbd.CHNO.sub.2)NHMe, aminopropyl, methylsulphonylmethyl or acetylamino; and R.sub.4 is 3-pyridinyl,6-methyl-3-pyridinyl or 4-methoxyphenyl.

Particularly preferred compounds are

1-[(3-amino-1-methyl-1H-1,2,4-triazol-5-yl)amino]-3-[3-(1-piperidinylmethyl )phenoxy]-2-propanol;

5-[[2-hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-1-methyl-1H-1 ,2,4-triazole-3-methanol;

2-[[2-hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-5-[(6-methyl- 3-pyridinyl)methyl]-4-(3H)-pyrimidinone;

2-[[2-hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-5-(3-pyridiny lmethyl)-4(3H)-pyrimidinone;

2-[[2-hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-5-[(4-methoxy phenyl)methyl]-4(3H)-pyrimidinone; and physiologically acceptable salts thereof.

The invention includes the compounds of formula (I) in the form of physiologically acceptable salts with inorganic and organic acids. Particularly useful salts include hydrochlorides, hydrobromides, sulphates, methanesulphonates, acetates,maleates, succinates, citrates, tartrates, fumarates and benzoates. The compounds of formula (I) and their salts may also form hydrates, which hydrates are also to be considered as part of the invention. The compounds of formula (I) can exhibittautomerism and the formula is intended to cover all tautomers. Where optical isomers may exist the formula is intended to cover all diastereoisomers and optical enantiomers. The term bioprecursors as used herein means compounds which have a structuredifferent to that of the compounds of formula (I) but which, upon administration to the animal or human being are converted in the body into a compound of formula (I).

The compounds according to the invention, preferably in the form of a salt may be formulated for administration in any convenient way and the invention includes within its scope pharmaceutical compositions containing at least one compoundaccording to the invention adapted for use in human or veterinary medicine. Such compositions may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers or excipients. Such compositions may also contain ifrequired other active ingredients, e.g. H.sub.1 -antagonists.

Thus the compounds according to the invention may be formulated for oral, buccal, topical, parenteral or rectal administration. Oral administration is preferred.

For oral administration, the pharmaceutical compositions may take the form of for example, tablets, capsules, powders, solutions, syrups or suspensions prepared by conventional means with acceptable excipients. For buccal administration thecomposition may take the form of tablets or lozenges formulated in conventional manner.

The compounds of the invention may be formulated for parenteral administration by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form in ampoules, or in multidose containers, with an addedpreservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient maybe in powder form for reconstitution with a suitable vehicle, e.g. sterile pyrogen-free water before use.

The compound of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glyceride.

For topical application, the compounds of the invention may be formulated as ointments, creams, gels, lotions, powders or sprays in a conventional manner.

For internal administration a convenient daily dosage regime of the compounds according to the invention would be 1 to 4 doses to the total of some 5 mg to 1.5 g per day, preferably 5 to 500 mg per day dependent upon the condition of the patient.

It will be appreciated that in the methods of the preparation of compounds of formula (I) given below, for certain reaction steps it may be necessary to protect various reactive substituents in the starting materials for a particular reaction andsubsequenly to remove the protecting group. Such protection and subsequent deprotection may be particularly pertinent where R.sub.1 and/or R.sub.2 in intermediates used to prepare compounds of formula (I) are hydrogen atoms and/or when R.sub.3 inintermediates is an alkyl group bearing a hydroxy substituent and/or when R.sub.7 in certain intermediates is an alkyl group bearing a hydroxy or primary or secondary amino substituent and/or when R.sub.5 in intermediates is a hydrogen atom. Standardprotection and deprotection procedures can be empolyed. For example an amino group may be protected by formation of a phthalimide which may subsequently be cleaved by treatment with a hydrazine e.g. hydrazine hydrate or a primary amine, for examplemethylamine; or by formation of a benzyl derivative which may subsequently be cleaved by hydrogenolysis in the presence of a catalyst e.g. palladium. The hydroxyl group OR.sub.5 where R.sub.5 is hydrogen may be protected, for example as an acyloxy groupor as an ether group such as trialkylsilyl e.g. trimethylsilyl, aralkyl such as benzyl, benzhydryl or trityl, tetrahydropyranyl or alkoxymethyl, e.g. methoxymethyl ethers. Such protecting groups may be removed by conventional procedures cf JFW McOmie. For example, benzyl and benzhydryl ether groups may be removed by catalytic hydrogenolysis with for example hydrogen and a palladium catalyst, and trityl, tetrahydropyranyl, alkoxymethyl and trialkylsilyl ether groups may be removed by acid hydrolysis.

In describing the processes which may be used for preparing the compounds of formula (I) or intermediates useful in the preparation thereof, any of R.sub.1 to R.sub.24, Alk, Q, Z, p, n and m are as defined in formula (I) unless otherwise stated.

Compounds of formula (I) may be prepared by cyclisation of an appropriate intermediate. Thus, compounds of formula (I) in which R.sub.5 represents hydrogen and Z represents the group ##STR9## where R.sub.7 is other than acyloxyalkyl, alkoxy,nitro, (CH.sub.2).sub.q N.dbd.CR.sub.15 R.sub.16, SO.sub.2 R.sub.17, COR.sub.20 (where R.sub.20 is hydrogen, aryl or aralkyl) or CR.sub.23 .dbd.NR.sub.24, may be prepared by cyclising a compound of formula (III) ##STR10## in which R.sub.25 is as definedfor R.sub.3, V' is ##STR11## or NCN and Y' is hydrogen where V is oxygen or sulphur and R.sub.7 ' is a group as defined for R.sub.7 or a group convertible thereto under the conditions of the cyclisation reaction or R.sub.7 ' represents halogen or alkoxy.

Thus for example in one embodiment of the cyclisation process a compound of formula (I) may be prepared by cyclisation of a compound of formula (IV) ##STR12## in which V' is NCN or NC(.dbd.V)R.sub.7 ' where R.sub.7 ' is as defined above, Vrepresents sulphur or more preferably oxygen and U represents two hydrogen atoms, in the absence or presence of a solvent, e.g. acetone or water, and optionally with heating.

It may be convenient to prepare in situ compounds of formula (IV) in which U represents two hydrogen atoms by treating a compound of formula (IV) where U represents a divalent protecting group which can readily be removed to yield two hydrogenatoms, for example a benzylidene group, with an acid, e.g. hydrochloric acid, optionally in the presence of an additional solvent, e.g. toluene and conveniently at a temperature of 10.degree.-50.degree. C. Under such conditions cyclisation to give thecorresponding compound of formula (I) will normally occur.

In general the intermediate of formula (IV) may be prepared from the appropriate diamines by methods analogous to those described in British Patent Specification Nos. 2047238A, 2023133A and 2075007A.

Compounds of formula (I) in which R.sub.5 is hydrogen and Z is other than --C(.dbd.X)NHR.sub.8 and when Z is ##STR13## then R.sub.7 represents nitro, may be prepared by heating the diamine (V) ##STR14## in which R.sub.5 represents hydrogen with acompound of formula (VI) or (VII) ##STR15## in which

R.sub.3 ' is the group R.sub.3 or a group convertible thereto, and

P and P' are leaving groups. Examples of the leaving group P are halogen, e.g. bromine and P' are nitroamino and alkylthio e.g. methylthio.

The reaction may be carried out in the absence or presence of a solvent such as acetonitrile, water, or an alcohol (e.g. ethanol) at for example 80.degree.-150.degree. C. and optionally in a sealed vessel.

In a particular embodiment of the process, triazoles in which R.sub.7 is NO.sub.2, i.e. q is zero and R.sub.6 is NO.sub.2, may be prepared by heating a diamine of formula (V) with a triazole of formula (VI) in which R.sub.7 is NO.sub.2.

Compounds of formula (VI) in which P is bromine may be prepared from the corresponding triazole (VI) in which P is hydrogen by treatment with bromine.

Compounds of formula (I) where Z represents ##STR16## and R.sub.5 represents hydrogen, may be made by reacting an amine of the formula (VIII)

with a compound of general formula (IX) ##STR17## wherein one of the groups R.sub.26 and R.sub.27 represents the group ##STR18## and the other represents the group R.sub.8, and L is a leaving group such as halogen, thioalkyl (preferablythiomethyl) or alkoxy.

Compounds of formula (IX) may be prepared by reacting the amine (VIII) with a compound of formula (X) ##STR19## where L is as defined in formula (IX).

The above reaction may be effected in the absence or presence of a solvent e.g. ethanol or water at a temperature from ambient to reflux preferably at room temperature. In the absence of a solvent the reaction may be carried out by heating amixture of the reactants at for example 100.degree.-120.degree. C.

Compounds of formula (I) in which R.sub.5 represents hydrogen, and Z represents ##STR20## where R.sub.7 is the group (CH.sub.2).sub.q R.sub.6 where R.sub.6 is NR.sub.10 COR.sub.13, NR.sub.10 SO.sub.2 R.sub.12, CH.sub.2 NHC(.dbd.X)NHR.sub.9 orN.dbd.CR.sub.15 R.sub.16 may be prepared by treating an aminoalkyltriazole of formula (XI) ##STR21## in which R.sub.1, R.sub.2, and R.sub.3 are as defined in formula (I) or are groups readily convertible thereto, and R.sub.28 is the group(CH.sub.2).sub.q NHR.sub.10 the group (CH.sub.2).sub.q+1 NH.sub.2 or the group (CH.sub.2).sub.q NH.sub.2, with a compound capable of replacing the hydrogen atom in the group NHR.sub.10 by the group COR.sub.13 or SO.sub.2 R.sub.12 or a hydrogen atom inthe group NH.sub.2 of the group (CH.sub.2).sub.q+1 NH.sub.2 by the group C(.dbd.X)NHR.sub.9 or both hydrogen atoms in the group NH.sub.2 of the group (CH.sub.2).sub.q NH.sub.2 by the group .dbd.CR.sub.15 R.sub.16.

Thus for example the aminoalkyltriazole (XI) in which R.sub.28 is the group (CH.sub.2).sub.q NHR.sub.10 may be reacted with an isocyanate R.sub.14 'NCO in which R.sub.14 ' has any of the meanings defined for R.sub.14 in formula (I) excepthydrogen or represents an alkali metal atom such as potassium or sodium, or with an activated derivative of either a carboxylic acid R.sub.13 COOH (in which R.sub.13 is other than the group NHR.sub.14) or a sulphonic acid R.sub.12 SO.sub.3 H to give acompound of formula (I) in which R.sub.6 is respectively the group NR.sub.10 CONHR.sub.14, NR.sub.10 COR.sub.13 (in which R.sub.13 is other than NHR.sub.14), or NR.sub.10 SO.sub.2 R.sub.12.

Suitable activated derivatives include acid halides e.g. acid chlorides, alkylchloroformates, acid anhydrides including mixed anhydrides (e.g. acetic formic anhydride), esters such as alkyl esters, ortho esters and (1-alkyl-2-pyridinyl)esters.

The reaction with an acid halide is preferably carried out in the presence of a base e.g. an inorganic base such as sodium hydroxide or an organic base such as triethylamine or pyridine. The reaction with an alkylchloroformate is preferablycarried out in the presence of a base, e.g. potassium carbonate or triethylamine, in a solvent such as dimethylformamide. The reaction with an acid anhydride may be carried out in the absence or presence of solvent such as pyridine.

In the reacion with an isocyanate, compounds of formula (I) in which R.sub.14 is other than hydrogen are conveniently prepared by carrying out the reaction in a solvent such as acetonitrile at temperatures from ambient to reflux. Compounds offormula (I) in which R.sub.14 is hydrogen may be prepared by heating a salt e.g. hydrochloride of the aminotriazole (XI) with an aqueous solution of an appropriate cyanate, e.g. potassium cyanate.

As a further embodiment of this process an aminoalkyltriazole (XI) in which R.sub.28 is the group (CH.sub.2).sub.q+1 NH.sub.2 may be treated with a compound of formula L'C(.dbd.X)NHR.sub.9 where L' is a leaving group (e.g. methylthio) to give acompound of formula (I) in which R.sub.6 is CH.sub.2 NHC(.dbd.X)NHR.sub.9. The reactants may for example be mixed in an aqueous solution at room temperature.

In yet another embodiment of this process an aminoalkyltriazole (XI) in which R.sub.28 is the group (CH.sub.2).sub.q NH.sub.2 is treated with an appropriate aromatic aldehyde, e.g. benzaldehyde, or a ketone R.sub.15 R.sub.16 CO to give a productin which R.sub.6 is N.dbd.CR.sub.15 R.sub.16. The reaction may conveniently be carried out in the presence of a solvent e.g. benzene, preferably with heating e.g. at reflux.

Compounds of formula (I) in which R.sub.5 is hydrogen and R.sub.7 is the group (CH.sub.2).sub.q R.sub.6 in which R.sub.6 is COR.sub.20 (where R.sub.20 is hydrogen, alkyl, aryl or aralkyl), or SO.sub.2 R.sub.17 may be prepared by oxidation of thecorresponding compound in which R.sub.7 is the group (CH.sub.2).sub.q CHR.sub.20 OH, (CH.sub.2).sub.q SR.sub.17 (where R.sub.17 is other than hydroxy) or (CH.sub.2).sub.q SH.

Thus aldehydes and ketones of formula (I) in which R.sub.5 is hydrogen and R.sub.7 is the group (CH.sub.2).sub.q COR.sub.20 where R.sub.20 is hydrogen, alkyl, aryl or aralkyl may be prepared by oxidising the corresponding hydroxyalkyl compound inwhich R.sub.7 is (CH.sub.2).sub.q CHR.sub.20 OH using for example oxalyl chloride and dimethylsulphoxide, or activated manganese dioxide in a solvent such as dichloromethane.

Compounds of formula (I) in which R.sub.5 is hydrogen and R.sub.7 is the group (CH.sub.2).sub.q SO.sub.2 R.sub.17 may be prepared by oxidising the corresponding compound in which R.sub.7 is either --(CH.sub.2).sub.q SR.sub.17 (where R.sub.17 isother than hydroxy) or (CH.sub.2).sub.q SH with for example peracetic acid. The reaction may be carried out in a solvent such as acetic acid, at room temperature.

The starting material in which R.sub.7 is (CH.sub.2).sub.q SH where q is other than zero may be obtained by alkaline hydrolysis of the corresponding isothiourea, which may in turn be prepared by alkylating thiourea with an appropriate compound offormula (I) in which R.sub.6 is a leaving group e.g. halo.

The thiol starting material in which R.sub.7 is SH may be prepared by diazotisation of the corresponding aminotriazole followed by treatment with an alkali metal (e.g. potassium) salt of ethyl xanthate to give a xanthate in which R.sub.7 is thegroup --SC(.dbd.S)OEt, which is subsequently hydrolysed (for example by heating with ethanolic potassium hydroxide) to give the starting thiol in which R.sub.7 is the group SH.

The above oxidation process is particularly applicable to the preparation of compounds of formula (I) in which there is no unsaturation within the groups R.sub.1 and R.sub.3.

Compounds of formula (I) in which R.sub.5 is hydrogen and R.sub.7 is (CH.sub.2).sub.q CR.sub.23 .dbd.NR.sub.24 may be prepared by reacting the corresponding carbonyl compound i.e. a compound of formula (I) in which R.sub.7 is (CH.sub.2).sub.qCOR.sub.23, with an appropriate reagent H.sub.2 NR.sub.24 in a suitable solvent such as ethanol, optionally with heating.

Compounds of formula (I) in which R.sub.5 is hydrogen, and R.sub.7 is the group (CH.sub.2).sub.q R.sub.6 where R.sub.6 is SO.sub.2 NR.sub.18 R.sub.19 or CONR.sub.21 R.sub.22 may be prepared by reacting an activated derivative of the correspondingcarboxylic acid or sulphonic acid, i.e. compounds of formula (I) in which R.sub.7 is (CH.sub.2).sub.q R.sub.6 where R.sub.6 is CO.sub.2 H or SO.sub.3 H, with ammonia or an appropriate amine HNR.sub.18 R.sub.19 or HNR.sub.21 R.sub.22. Suitable activatedderivatives include those referred to previously e.g. acid chlorides and esters.

Compounds of formula (I) in which R.sub.7 is an acyloxyalkyl group and/or R.sub.5 is acyl may be prepared by treating the corresponding compound of formula (I) in which R.sub.7 is a hydroxyalkyl group and/or R.sub.5 represents hydrogen witheither an appropriate acid or an activated derivative thereof (e.g. an acid anhydride or acid chloride). The reaction may be carried out at room temperature optionally in the presence of a solvent (e.g. pyridine, tetrahydrofuran, acetone ordimethylformamide), and preferably in the presence of a base (e.g. pyridine, triethylamine or an alkali metal carbonate such as potassium carbonate).

Compounds of formula (I) in which Z is ##STR22## Alk is CH.sub.2 and R.sub.5 is hydrogen may be prepared by treating an aldehyde of formula (XII) ##STR23## with an amine R.sub.1 R.sub.2 NH in a solvent such as tetrahydrofuran or an alkanol, e.g.methanol, followed by reduction using for example a hydride reducing agent such as an alkali or alkaline earth metal borohydride e.g. sodium borohydride or lithium aluminium hydride, or hydrogen and a metal catalyst such as palladium or platinum. Thereactions may be carried out at a temperature of 0.degree. to 30.degree. C.

The intermediates of formula (XII) may be prepared from compounds of formula (XIII) ##STR24## in which W represents a protected aldehyde group, e.g. a cyclic acetal such as an ethylene acetal, by methods analogous to those described herein forpreparing compounds of formula (I) from the amine of formula (V).

Compounds of formula (I) in which R.sub.5 is hydrogen and R.sub.6 is tetrahydropyranyloxy may be prepared by reacting the corresponding hydroxyalkyltriazole of formula (I) with dihydropyran. The reaction may be carried out in a solvent, e.g.dichloromethane or dimethylformamide, at low temperature e.g. -10.degree. to 0.degree. C., in the presence of a catalyst, e.g. paratoluenesulphonic acid.

In the above discussion of the processes available for the production of compounds according to the invention reference has been made to the primary amines of formula (V). These amines are novel compounds and the invention includes suchcompounds. These intermediates may be made by a number of processes which are described below.

Diamines of formula (V) in which R.sub.5 is hydrogen and n is 1 may be prepared by reacting a compound of formula (XIV)

with an epoxide of formula (XV) ##STR25## to produce a diamine of formula (XVI) ##STR26##

The reaction may be carried out in the absence or presence of a solvent such as dimethylformamide, preferably at elevated temperature, and optionally in the presence of a base, e.g. sodium hydride or potassium butoxide. The protecting group maybe removed from the compound of formula (XVI) by reaction with a hydrazine, e.g. hydrazine hydrate, or a primary amine, e.g. methylamine.

Diamines of formula (V) in which R.sub.5 is hydrogen and m is 1 may be prepared by reacting an epoxide of formula (XVII) ##STR27## with an azide, e.g. sodium azide to produce a compound of formula (XVIII) ##STR28## which may be reduced to producea diamine of formula (V) where m is 1. The reaction with the azide may be carried out in a suitable solvent, e.g. aqueous ethanol in the presence of ammonium chloride, preferably at reflux temperature. Reduction of the compound of formula (XVIII) maybe carried out for example, with lithium aluminium hydride in a suitable solvent, e.g. tetrahydrofuran, or catalytically using for example platinum oxide or palladium oxide as catalyst.

Diamines of formula (V) in which R.sub.5 is hydrogen and m is 2 may be prepared by reacting the epoxide of formula (XVII) with a cyanide, e.g. sodium cyanide, to produce a compound of formula (XIX) ##STR29## which may be reduced to produce acompound of formula (V) in which m is 2. The reaction with the cyanide may be carried out in a suitable solvent, e.g. aqueous ethanol preferably at reflux temperature. Reduction of the compound of formula (XIX) may be carried out, for example withlithium aluminium hydride in a suitable solvent, e.g. tetrahydrofuran. Alternatively the epoxide of formula (XVII) may be reacted with nitromethane to produce a compound of formula (XX) ##STR30## which may be reduced to produce a compound of formula (V)in which m is 2. The reaction with nitromethane may be carried out in a suitable solvent, e.g. dimethylformamide, preferably in the presence of a base, e.g. sodium hydride. Reduction of the compound of formula (XX) may be carried out for example asdescribed above for reduction of the compound of formula (XIX) or using hydrogen in the presence of a catalyst.

The intermediate epoxides of formula (XVII) may be prepared by alkylation of an appropriate alkali metal phenolate, e.g. sodium phenolate with a halohydrin (XXI) ##STR31##

The intermediate epoxide of formula (XV) may be prepared by alkylation of an alkali metal, phthalimide, e.g. potassium phthalimide with a halohydrin (XXII) ##STR32##

Where the product of any of the above processes is a free base and a salt is required, the salt may be formed in conventional manner. Thus, for example, a generally convenient method of forming the salts is to mix appropriate quantities of thefree base and the acid in an appropriate solvent(s) e.g. an alcohol such as ethanol or an ester such as ethyl acetate.

The invention is illustrated but not limited by the following Examples.

In the following Examples and Preparations temperatures are in .degree.C.

T.l.c. refers to thin layer chromatography and this and preparative chromatography were carried out on silica using, unless otherwise stated, one of the following solvent systems.

System A: Dichloromethane:ethanol:0.88 ammonia (50:8:1)

System B: Dichloromethane:ethanol:0.88 ammonia (100:8:1)

System C: Methanol:0.88 ammonia (200:1).

Preparation 1

2-[2-Hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]-1H-isoindole-1,3-(2H )dione

(a) A mixture of 2-(oxiranylmethyl)-1H-isoindole-1,3-(2H)-dione (9.10 g) and 3-(1-piperidinylmethyl)phenol (8.55 g) was heated at 130.degree. C. under nitrogen for 10 minutes. The resulting mixture was dissolved in chloroform (100 ml), washedwith 1N sodium hydroxide (2.times.25 ml), dried (MgSO.sub.4) and evaporated to give the title compound as a gum (17.65 g).

T.l.c. system B, Rf 0.60.

(b) Similarly prepared by this procedure from 2-[2-oxiranylethyl]-1H-isoindole-1,3-(2H)dione (19.7 g) and 3-(1-piperidinylmethyl)phenol (17.4 g) except that the crude compound was distilled, was3-hydroxy-[4-[3-(1-piperidinylmethyl)phenoxy]butyl]-1H-isoindole-1,3-(2H)- dione (16.5 g) as an orange oil, b.p. 180.degree. C. (0.05 mm).

N.m.r. (CDCl.sub.3): 2.0-2.35, m(4H); 2.8, t, (dd), (1H); 3.33, m, (3H); 5.8-6.2, m, (5H); 6.54, s, (2H); 6.95, br, (1H), 7.5-7.7, m, (4H); 7.8-8.2, m, (2H); 8.2-8.7, m, (6H).

Preparation 2

1-Amino-3-[3-[(1-piperidinylmethyl)]phenoxy]-2-propanol

(a) A solution of 2-[2-hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]-1H-isoindole-1,3-(2 H) dione (17.6 g) and hydrazine hydrate (2.5 g) in ethanol (60 ml) was heated under reflux for 3 h. The resulting mixture was evaporated to a solidresidue which was suspended in 1N hydrochloric acid (30 ml) and filtered. The filtrate was basified with an excess of potassium carbonate and extracted with isopropanol (3.times.40 ml). The isopropanol extracts were dried (Na.sub.2 CO.sub.3) andevaporated to a gum which was chromatographed using System A. Crystallisation of the product from n-hexane:ether (20:1) gave the title compound as colourless grains (7.7 g), m.p. 74.degree.-76.5.degree..

(b) Similarly prepared by this procedure from 3-hydroxy-[4-[3-(1-piperidinylmethyl)phenoxy]butyl]-1H-isoindole-1,3-(2H)- dione (16.5 g) and hydrazine hydrate (4.35 g) (except that the crude product was distilled [b.p. 200.degree. (0.06 mm)])was 4-amino-1-[3-(1-piperidinylmethyl)phenoxy]-2-butanol (7.2 g) as a white solid, m.p. 59.degree..

(c) Similarly prepared by this procedure from 2-[3-[3-(dimethylaminomethyl)phenoxy]-2-hydroxy-propyl]-1H-isoindole-1,3-( 2H)-dione (13.0 g) and hydrazine hydrate (2.1 g) except the crude product was distilled [b.p. 200.degree., 0.2 mmHg] was1-amino-3-[3-(dimethylaminomethyl)phenoxy]-2-propanol (3.8 g) as a pale yellow solid.

n.m.r. (CDCl.sub.3): 2.7, t, (1H); ca. 3.2, m, (3H); ca. 6.05, m, (3H); 6.63, s, (2H); 7.15, m, (2H); 7.53, br, m, (2H); 7.78, s, (6H); 7.0-8.3, br, s, (1H).

Preparation 3

2-[3-[3-(Dimethylaminomethyl)phenoxy]-2-hydroxy-propyl]-1H-isoindole-1,3-(2 H)-dione

A solution of 2-(oxiranylmethyl)-1H-isoindole-1,3-(2H)-dione (20.3 g) and 3-(dimethylaminomethyl)phenol (22.3 g) in dimethylformamide (200 ml) with a catalytic amount of sodium hydride (0.2 g) was heated for 6 h at 100.degree. under N.sub.2. The solvent was evaporated to give an oil which was dissolved in chloroform and washed with 2N sodium hydroxide and water. The organic solution was evaporated to give an oil (14 g). A portion of the oil (0.8 g) was distilled to give the title compound(0.6 g) as an oil, b.p. 250.degree. (0.08 mmHg).

Found: C, 67.4; H, 6.3; N, 7.8; C.sub.20 H.sub.22 N.sub.2 O.sub.4 requires: C, 67.8; H, 6.3; N, 7.9%.

Preparation 4

1-Amino-4-[3-(1-piperidinylmethyl)phenoxy]-2-butanol

(a) 1-[[3-(2-Oxiranylethoxy)phenyl]methyl]piperidine

A mixture of 3-(1-piperidinylmethyl)phenol (19.1 g) and flaked potassium hydroxide (6.1 g) in acetonitrile (350 ml) was stirred at room temperature for 16 h. The mixture was warmed to give a uniform solution to which (2-bromoethyl)oxirane (20 g)was added. After 3.5 h at ambient temperature, the solvent was evaporated off and the residue partitioned between diethyl ether (400 ml) and water (100 ml). The organic phase was washed with 1M sodium hydroxide, dried and evaporated at 50.degree. (0.01 mm) to give the title compound (18 g) as a light brown oil.

m.n.r. (CDCl.sub.3): 2.7-3.4, t+m, (4H); 5.93, t, (2H); 6.6, s, (2H); 6.9, m, (1H); 7.23+7.47, t+dd, (2H); ca. 7.65, m, (4H); ca. 8.0, m, (2H); ca 8.6, m, (6H).

(b) 1-Azido-4-[3-(1-piperidinylmethyl)phenoxy]-2-butanol

A solution of 1-[[3-[2-oxiranylethoxy]phenyl]methyl]piperidine (17 g), sodium azide (5.1 g) and ammonium chloride (2.73 g) in 25% aqueous ethanol (200 ml) was refluxed for 6 h and concentrated to ca. 130 ml. The concentrate was diluted withwater (50 ml), saturated with potassium carbonate and extracted with isopropanol. The extract was dried and evaporated to given an oil (20 g) which was chromatographed on silica using dichloromethane:ethanol:ammonia (200:8:1) to give the title compound(10.5 g) as a colourless oil.

n.m.r. (CDCl.sub.3): 2.75, t, (1H); 3.0-3.3, m, (3H); ca. 5.85, m, (3H); 6.53, s, (2H); 6.58, d, (2H); 7.2, br s, (1H); 7.65, m, (4H); 8.05, m, (2H); ca. 8.5, m, (6H).

(c) 1-Amino-4-[3-(1-piperidinylmethyl)phenoxy]-2-butanol

A solution of 1-azido-4[3-(1-piperidinylmethyl)phenoxy]-2-butanol (10 g) in dry tetrahydrofuran (100 ml) was added dropwise to a stirred suspension of lithium aluminium hydride (4 g) in tetrahydrofuran (200 ml) under nitrogen. The resultingmixture was stirred at room temperature for 1 h and quenched with water (4 ml), followed by 15% sodium hydroxide (4 ml) and water (12 ml). The mixture was then filtered and the residue washed with tetrahydrofuran (50 ml). The combined filtrate wasevaporated to give the title compound (7.5 g) as a pale pink oil.

n.m.r. (CDCl.sub.3): 2.78, t, (1H); 3.0-3.32, m, (3H); 5.88, t, (2H); 6.22, m, (1H), 6.58, s, (2H); 7.0-7.5, ABX, (2H), 7.6, m, (4H), 7.73, brs, (3H); 8.1, m, (2H); ca. 8.5, m, (6H).

EXAMPLE 1

1-[(3-Amino-1-methyl-1H-1,2,4-triazol-5-yl)]amino-3-[3-(1-piperidinylmethyl )phenoxy]-2-propanol, maleate (1:2)

A mixture of 1-amino-3-[(1-piperidinylmethyl)phenoxy]-2-propanol (1.32 g) and methyl N-cyano-1-methyl-2-(phenylmethylene)hydrazine-carboximidothioate (1.16 g) was heated as a melt at 80.degree. C. under water pump vacuum until bubbling ceased(20 minutes). The resulting mixture was stirred with toluene (20 ml) and 1N hydrochloric acid (10 ml) for 30 minutes. The aqueous phase was diluted with water (30 ml), brought to pH 9 by addition of potassium carbonate, and washed with toluene(2.times.40 ml). The aqueous layer was treated with an excess of potassium carbonate and extracted with ethyl acetate (3.times.25 ml). The ethyl acetate extracts were dried (Na.sub.2 SO.sub.4) and evaporated to a gum which was purified by columnchromatoraphy using System A. The resulting gum was treated with an excess of maleic acid in isopropanol to yield the title compound as a white solid (1.52 g), m.p. 145.degree.-7.degree..

Found: C, 52.4; H, 6.1; N, 13.9; C.sub.26 H.sub.36 N.sub.6 O.sub.10 requires: C, 52.9; H, 5.8; N, 14.2%.

EXAMPLE 2

5-[[2-hydroxy-3-[3-(1-pieridinylmethyl)phenoxy]propyl]amino]-1-methyl-1H-1, 2,4-triazole-3-methanol

A solution of 1-amino-3-[(1-piperidinylmethyl)phenoxy]-2-propanol (compound A) (1.32 g) and methyl N-[2-(acetyloxy)acetyl]-1-methyl-2-(phenylmethylene)-hydrazinecarboximidot hioate (Compound B) (1.61 g) in toluene was stirred at 25.degree. C.for 4 h. The resulting solution was treated with 5N hydrochloric acid and stirred for 18 h. The aqueous layer was adjusted to pH 9 by addition of sodium hydroxide and washed with toluene. The aqueous layer was treated with an excess of sodium hydroxideand extracted with hot methyl isobutyl ketone which on cooling gave a white precipitate. Recrystallisation from isopropanol gave the title compound as a white solid (0.81 g) m.p. 170.degree.-2.degree..

Analysis Found: C, 60.8; H, 7.7, N, 18.3; C.sub.19 H.sub.29 N.sub.5 O.sub.3 requires: C, 60.8; H, 7.8; N, 18.7%.

(b) Similarly prepared by this procedure from compound A (0.8 g) and methyl 1-methyl-N-[(methylsulphonyl)acetyl]-2-(phenylmethylene)hydrazine-carboxim idothioate (1.1 g), except that the methyl isobutyl ketone extract was evaporated to give aresidue which was chromatographed using system A to give a gum which crystallised from methyl acetate-light petroleum (b.p. 60.degree.-80.degree.), was 1-[(1-methyl-3-methylsulphonylmethyl-1H-triazol-5-yl)amino]-3-[3-(1-piperidinylmethyl)phenoxy]-2-propanol, (0.49 g) as a white solid m.p. 68.degree..

N.m.r. (CDCl.sub.3): 2.8, t, (1H); 2.95-3.35, m, (3H); 5.22, t, (1H); 5.78, s, (2H); 5.97, d, (2H); 5.9, m, (1H); 6.3, d, (2H); 6.43, s, (3H); 6.55, s, (2H); 6.9, s, (3H); 7.6, m, (4H); 8.45, m, (6H).

(c) Similarly prepared by this procedure from 4-amino-1-[3-(1-piperidinylmethyl)phenoxy]-2-butanol (2.0 g) and compound B (2.4 g), was 1-methyl-5-[3-hydroxy-[4-[3-(1-piperidinylmethyl)phenoxy]butyl]amino]-1H-1 ,2,4-triazole-3-methanol (1.7 g) asa white solid, m.p. 128.degree..

Found: C, 61.7; H, 8.0; N, 17.7; C.sub.20 H.sub.31 N.sub.5 O.sub.3 requires: C, 61.7; H, 8.0; N, 18.0%.

(d) Similarly prepared by this procedure from 1-amino-3-[3-(dimethylaminomethyl)phenoxy]-2-propanol (1.5 g) and compound B (2.25 g) except that the methyl isobutyl ketone extract was evaporated to give a solid which was washed with diethyl etherand then recrystallised from methyl acetate was 5-[[3-[3-(dimethylaminomethyl)phenoxy]-2-hydroxy-propyl]amino]-1-methyl-1H -1,2,4-triazole-3-methanol (250 mg) m.p. 104.degree.-109.degree..

N.m.r, (CD.sub.3 OD): 2.7-3.55, m, (4H); 5.7, s, (2H); 5.8-6.3, m, (3H); 6.45-6.75, m, (7H); 7.9, s, (6H).

EXAMPLE 3

1-[[3-(3-Aminopropyl)-1-methyl-1H-1,2,4-triazol-5-yl]amino]-3-[3-(1-piperid inylmethyl)phenoxy]-2-propanol

2-[3-[5-[[2-Hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-1-methy l-1H-1,2,4-triazol-3-yl]propyl]-1H-isoindole-1,3(2H)-dione

A solution of methyl-N-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-oxobutyl]-1-methyl- 2-(phenylmethylene)hydrazinecarboximidothioate, (2.1 g) and 1-amino-3-[(1-piperidinylmethyl)phenoxy]-2-propanol (1.32 g) in toluene (10 ml) was stirred atroom temperature 6H. The mixture was then treated with 5N hydrochloric acid (10 ml) at room temperature for 21 h and a further quantity of 5N hydrochloric acid (5 ml) was added and stirred for further 20 h. The reaction mixture was then washed withtoluene, basified with sodium bicarbonate (pH 9) and extracted with ethyl acetate. The extract was dried and evaporated to leave a light brown gum (1.9 g) which was chromatographed using system A to give the title compound (0.8 g) as a yellow gum.

n.m.r. (CDCl.sub.3): 2.2, m, (4H); 2.84, t, (1H); 3-3.35, m, (3H); 5.25, t, (1H); 4.6-5.8, br, (1H); 5.7-6.8, m, (12H); 7.25-8.15, m, (8H); 8.2-8.7, m, (6H).

1-[[3-(3-Aminopropyl)-1-methyl-1H-1,2,4-triazol-5-yl]amino]-3-[3-(1-piperid inylmethyl)phenoxy]-2-propanol

A solution of 2-[3-[5-[[2-hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-1-meth yl-1H-1,2,4-triazol-3-yl]propyl]-1H-isoindole-1,3-(2H)-dione (0.8 g) and hydrazine hydrate (0.5 ml), in ethanol (60 ml) was stirred at room temperature for 4h and the solvent removed in vacuo. The white solid residue was partitioned between diethyl ether (100 ml) and 5M sodium hydroxide (50 ml). The alkaline aqueous phase was further extracted with ethyl acetate. The organic extracts were combined, washedwith 5M sodium hydroxide (50 ml), dried and evaporated to give a yellow gum (0.65 g) which was chromatographed on silica using methanol: 0.88 ammonia (80:1) to give the title compound (0.25 g) as a light brown gum.

n.m.r. (CDCl.sub.3): 2.8, dd(t), (1H); 3.01-3.33, m, (3H); 5.37, t, (1H); 5.8-6.16, m, (3H); 6.3-6.62, m, (6H); 7.05-7.8, m, (12H); 8.2-8.72, m, (8H).

i.r. (CHCl.sub.3): 3600, 3445, 2800, 2755, 2720, 1595 cm.sup.-1.

EXAMPLE 4

5-[2-acetyloxy-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-1-methyl-1H -1,2,4-triazole-3-methanol acetate (ester)

A solution of 5-[2-hydroxy-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-1-methyl-1H- 1,2,4-triazole-3-methanol (0.75 g) in acetic acid (30 ml) was refluxed for 48 h. The solution was evaporated to leave a pale yellow oil. Aqueous sodiumbicarbonate solution (2M, 100 ml) was added and the mixture was extracted with ethyl acetate. The extract was dried and evaporated to give the title compound (0.89 g) as a yellow gum.

N.m.r. (CDCl.sub.3); 2.78, t, (dd), (1H); 3.0-3.35, m, (3H); 4.65, m, (1H); 5.03, s, (2H); 5.51, t, (1H); 5.82, d, (2H); 6.1-6.3, m, (2H); 6.45, s, (3H); 6.58, s, (2H); 7.5-7.7, m (4H); 7.90, s, (6H); 8.3-8.7, m, (6H).

I.r. (CHBr.sub.3): 3400, 1740, 2800, 2760, 2720 cm.sup.-1.

EXAMPLE 5

1-[(3-Amino-1H-1,2,4-triazol-5-yl)amino]-3-[3-(1-piperidinylmethyl)phenoxy] -2-propanol hemihydrate

Methyl N-cyano-[2-hydroxy-3-[3-[(1-piperidinyl)methyl]phenoxy]propyl]carbamimidot hioate

A solution of 1-amino-3-[(1-piperidinylmethyl)phenoxy]-2-propanol (2.6 g) in ether (50 ml) and methanol (10 ml) was added dropwise to a solution of dimethyl cyanocarbonimidodithioic acid (1.5 g) in ether (30 ml) and the mixture was stirred atroom temperature for 18 h. The mixture was filtered and the filtrate was evaporated to give a gum which was chromatographed using System B to give the title compound (1.32 g) as a pale yellow gum.

N.m.r. (CDCl.sub.3): 2.8, t, (1H); 2.9-3.4, m, (3H); 4.8, m, (1H); 5.8, m, (2H); 6.1, m, (2H); 6.3, s, (2H); 7.35, s, (3H); 7.6, m, (4H); ca. 8.5, m, (6H).

1-[(3-Amino-1H-1,2,4-triazol-5-yl)amino]-3-[3-(1-piperidinylmethyl)phenoxy] -2-propanol hemihydrate

Hydrazine hydrate (0.9 ml, 18.5 mmol) was added to a stirred solution of methyl N-cyano-[2-hydroxy-3-[3-[(1-piperidinyl)methyl]phenoxy]propyl]carbamimidot hioate (1.25 g, 3.5 mmol) in ethanol (10 ml). After 18 h at room temperature the mixturewas evaporated to give a gum (1.3 g) which was chromatographed on silica using methanol:0.88 ammonia (100:1) to give the title compound (0.96 g) as a solid white foam, m.p. 57.degree. (softens).

N.m.r. (CD.sub.3 OD): 2.82, t, (dd), (1H); 3.0-3.3, m, (3H); 5.8-6.15, m, (3H); 6.60, s, (2H); 6.7, m, (2H); 7.60, m, (4H); 8.3-8.7, m, (6H).

EXAMPLE 6

2-[[2-Hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-5-[(6-methyl- 3-pyridinyl)methyl]-4-(3H)-pyrimidinone

(a) A mixture of 5-(6-methyl-3-pyridinylmethyl)-2-methylthio-4(3H)-pyrimidinone (1.24 g) and 1-amino-3-[3-[1-piperidinylmethyl]phenoxy]-2-propanol (Compound A) (1.32 g) was heated at 120.degree. for 1.5 h and then at 130.degree.-140.degree. for2.5 h. The resulting brown glass was dissolved in chloroform (25 ml) and added to stirred dry diethyl ether (250 ml) to precipitate a white solid (1.5 g). This solid was recrystallised from ethyl acetate to give the title compound (0.9 g) as a whitesolid, m.p. 115.degree.-117.degree..

N.m.r. (CDCl.sub.3): 1.0-3.0, v,. br., (3H); 1.5, d, (1H); 2.53-2.69, s+dd, (2H); 2.82, t, (1H); 2.99, d, (1H); 3.10-3.3, m, (3H); 5.8-6.1, m, (3H); 6.25-6.58, ABq+s, (6H); 7.54, s, (3H); 7.65, br, (4H); 8.4-8.6, br, (6H).

Similarly prepared by this procedure were:

(b) From compound A (0.9 g) and 5-(3-pyridinylmethyl)-2-methylthio-4(3H)-pyrimidinone (0.8 g), except that the mixture was heated at 125.degree.-130.degree. for 2.5 h and subsequently at 140.degree.-150.degree. for 3 h and the crude product(0.92 g) was chromatographed using System C was 2-[[2-hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-5-(3-pyridin ylmethyl)-4(3H)-pyrimidinone monohydrate (0.42 g) as a buff solid m.p. (78.degree.-82.degree.) (softens).

Found: C, 64.3; H, 6.9; N, 14.6; C.sub.25 H.sub.31 N.sub.5 O.sub.3.H.sub.2 O requires: C, 64.2; H, 7.1; N, 15.0%.

(c) From compound A (0.4 g) and 5-[(4-methoxy phenyl)methyl]-2-(methylthio)-4(3H)-pyrimidinone (0.42 g), except that the crude product was chromatographed using System C and then crystallised from methyl acetate and light petroleum (b.p. 60.degree.-80.degree.), was 2-[[2-hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-5-[(4-methox yphenyl)methyl]-4(3H)-pyrimidinone (0.26 g) as a white solid, m.p. 112.degree.-116.degree..

n.m.r. (CDCl.sub.3): 2.2-3.4, m, (12H); 2.7-3.4, m, (9H); 5.95-6.15, m+d, (3H); 6.3, s, (3H); 6.6, m, (6H); 7.7, m, (4H); 8.6, m, (6H).

EXAMPLE 7

1-[[1-(Methylamino)-2-nitroethenyl]amino]-3-[3-(1-piperidinylmethyl)phenoxy ]-2-propanol

(a) A solution of 1-amino-3-[(1-piperidinylmethyl)phenoxy]-2-propanol (1.32 g) and N-methyl-1-(methylthio)-2-nitroethenamine (1.04 g) in water (25 ml) was stirred at 25.degree. for 24 h. The resulting mixture was treated with glacial acetic acid(2 ml) and was washed with ethyl acetate. The aqueous phase was basified with excess potassium carbonate and extracted with ethyl acetate. The extract was dried and evaporated to give a gum which was crystallised from acetone to give the title compound(820 mg) as a white solid, m.p. 104.degree.-5.degree..

N.m.r. (CDCl.sub.3 -DMSO): -0.3, br, s, (1H); 2.81, dd, (1H); 3.0-3.5, m, (4H); 5.7-6.1, m, (3H); 6.4-6.6, m, (2H); 6.6, s, (2H); 7.2, br s, (3H); 7.5-7.8, m, (4H); 8.3-8.7, m, (6H).

(b) Similarly prepared by this procedure from 4-amino-1-[3-(1-piperidinylmethyl)phenoxy]-2-butanol (2.0 g) and N-methyl-1-(methylthio)-2-nitroethenamine (1.5 g) except that the gum was chromatographed using system B was4-[[1-(methylamino)-2-nitroethenyl]amino]-1-[3-(1-piperidinylmethyl)phenox y]-2-butanol (1.1 g) as a white foam, m.p. 45.degree.-50.degree..

n.m.r. (CD.sub.3 OD): -0.2, br, (1H); 0.32, br, (1H); 2.85, t, (1H); 3.0-3.5, m+s, (4H); 5.9-6.2, m, (3H); ca. 6.6, m+s, (4H); 7.2, brs, (3H); 7.7, m, (4H); 8.2, m, (2H); ca. 8.6, m, (6H).

EXAMPLE 8

1-[[3-(Acetylamino)-1-methyl-1H-1,2,4-triazol-5-yl]amino]-3-[3-(1-piperidin ylmethyl)phenoxy]-2-propanol acetate (ester)

A solution of 1-[[3-amino-1-methyl-1H-1,2,4-triazol-3-yl]amino]-3-[3-(1-piperidinylmethy l)phenoxy]-2-propanol (1.0 g) and acetic anhydride (0.62 g) in pyridine (30 ml) was stirred at 23.degree. C. for 18 h. The solvent was evaporated to give agum, which was dissolved in ethyl acetate. This solution was washed with saturated sodium carbonate solution, dried and evaporated to give a foam, which was chromatographed using system B to give the title compound (0.5 g) as a white foam.

n.m.r. (CD.sub.3 OD): 2.7-3.3, m, (4H); 4.6, m, (1H); 5.9, m, (2H); 6.25-6.65, m, (7H); 7.6, m, (4H); 7.9-8.0, s+s, (6H); 8.5, m, (6H).

i.r. (CHBr.sub.3): 3425, 3405, 2800, 2760, 2720, 1735, 1708, 1678, 1610 cm.sup.-1.

EXAMPLE 9

N-[5-[[2-Hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-1-methyl-1 H-1,2,4-triazol-3-yl]acetamide hemihydrate

A solution of 1-[[3-(acetylamino)-1-methyl-1H-1,2,4-triazol-5-yl]amino]-3-[3-(1-piperidi nylmethyl)phenoxy]-2-propanol acetate (ester) (0.32 g) and 0.9M aqueous potassium hydroxide (1.0 ml) in ethanol (25 ml) was stirred for 0.5 h at 23.degree.. The ethanol was evaporated, and the residue was suspended in sodium carbonate solution. This solution was extracted with methyl acetate. The extract was dried, and evaporated to give a gum, which was chromatographed using system A to give the titlecompound (0.25 g) as a white foam.

Found: C, 58.5; H, 7.7; N, 20.1; C.sub.20 H.sub.30 N.sub.6 O.sub.3.0.5H.sub.2 O requires: C, 58.4; H, 7.6; N, 20.4%.

N.m.r. (CDCl.sub.3): 2.6-3.3, m, (4H); 5.7-6.15, m, (7H); 6.4-6.6, m, (7H); 7.6, m, (4H); 7.9, s, (3H); 8.5, m, (6H).

EXAMPLE 10

1-[[1-Methyl-3-[3-[[1-(methylamino)-2-nitroethenyl]amino]propyl]-1H-1,2,4-t riazol-5-yl]amino]-3-[3-(1-piperidinylmethyl)phenoxy]-2-propanol

A solution of 1-[[3-(3-aminopropyl)-1-methyl-1H-1,2,4-triazol-5-yl]amino]-3-[3-(1-piperi dinylmethyl)phenoxy]-2-propanol (0.25 g) and N-methyl-1-(methylthio)-2-nitroethenamine (0.1 g) in water (6 ml) and methanol (6 ml) was stirred at roomtemperature for 24 h. A further quantity of N-methyl-1-(methylthio)-2-nitroethenamine (0.01 g) was added and the mixture stirred for a further 3 h. The reaction mixture was concentrated to ca. 6 ml, diluted with water (10 ml), acidified to pH3 withacetic acid and washed with ethyl acetate. The aqueous solution was basified with excess potassium carbonate and extracted with ethyl acetate. The extract was dried and evaporated to leave a brown gum which was chromatographed on silica usingmethanol:ammonia (250:1) to give a gum which was dissolved in hot ethyl acetate and cooled to precipitate a gum. This gum was dissolved in chloroform and filtered through florosil and hyflo. The filtrate was evaporated to give the title compound (0.12g) as a solid white foam m.p. 60.degree.-63.degree. (softens).

n.m.r. (CDCl.sub.3): -0.2, brs, (1H), 2.25, brs, (1H); 2.8, t, (1H); 3.1, m, (2H); 3, 24, dd, (1H); 3.28-3.45, m, (2H); 4.4, brs, (1H); 5.75, brs, (1H); 5.95, m, (2H); 6.1-6.9, m, (9H); 7.0-7.5, m, (5H); 7.63, m, (4H); 8.05, m, (2H); 8.4-7.8, m,(6H).

EXAMPLE 11

1-[[1-Methyl-3-[(phenylmethylene)amino]-1H-1,2,4-triazol-5-yl]amino]-3-[3-( 1-piperidinylmethyl)phenoxy]-2-propanol

A solution of 1-[(3-amino-1-methyl-1H-1,2,4-triazol-5-yl)amino]-3[3-(i-piperidinylmethyl )phenoxy]-2-propanol (0.47 g) and benzaldehyde (0.2 g) in benzene (15 ml) was refluxed for 18 h and evaporated to leave a brown gum (0.65 g). This gum (0.33g) was chromatographed on alumina using diethyl ether:ethyl acetate:methanol (20:20:1) to give the title compound (0.09 g) as a yellow foam. m.p. 53.degree.-57.degree. (softens).

n.m.r. (CDCl.sub.3): 0.9, s, (1H); 2.1-2.6, m+m, (5H); 2.8, t, (1H); 3.0-3.35, m, (3H); 5.15, brt, (1H); 5.4-6.1, m, (4H); 6.2-6.6, m, (7H); 7.5, m, (4H); 8.5, m, (6H).

EXAMPLE 12

N-Cyano-N'-[2-hydroxy-3-[3-(1-piperidinylmethyl)phenoxy]propyl]-N"-methylgu anidine

A mixture of 1-amino-3[(1-piperidinylmethyl)phenoxy]-2-propanol (1 g) and methyl N-cyano-N'-methyl-carbamimidothioate (0.49 g) was heated at 100.degree. under water pump vacuum for 4 h. The resulting brown glass was chromatographed on silicausing dichloromethane:ethanol:ammonia (100:8:1) to give a brown gum (0.75 g). This gum was further purified by chromatography using methanol:ammonia (250:1) to give the title compound (0.27 g) as a white solid foam, m.p. 45.degree.-7.degree. softens.

n.m.r. (CDCl.sub.3): 2.8, t, (1H); 3.03-3.37, m, (3H); 3.63, q, (1H); 3.91, t, (1H); 5.8-6.2, m, (3H); 6.47-6.79, m, (4H); 7.22, d, (3H); 7.68, m, (4H); 8.52, m, (6H).

EXAMPLE 13

5-[[2-Hydroxy-4-[3-(1-piperidinylmethyl)phenoxy]-butyl]amino]-1-methyl-1H-1 ,2,4-triazole-3-methanol

A solution of 1-amino-4-[3-(1-piperidinylmethyl)phenoxy]-2-butanol (1.4 g) and methyl N-[2-(acetyloxy)acetyl-1-methyl]-2-(phenylmethylene)-hydrazine-carboximido thioate (1.61 g) in toluene (20 ml) was stirred at 25.degree. for 3 h. The solutionwas treated with 5N hydrochloric acid (10 ml) and stirred for 16 h. The phases were separated, the aqueous phase was washed with toluene, basified with excess 2N sodium hydroxide and ethyl acetate (50 ml) was added. The liquid phases were decanted offfrom the resulting white solid which was recrystallised from ethyl acetate-methanol to give the title compound (193 mg) as white crystals, m.p. 147.5.degree.-148.degree..

Found: C, 61.6; H, 8.1; N, 17.8; C.sub.20 H.sub.31 N.sub.5 O.sub.3 requires: C, 61.7; H, 8.0; N, 18.0%.

Examples of Pharmaceutical Compositions

______________________________________ 1. Tablets mg/tablet ______________________________________ Active ingredient 5.0 to 25.0 Lactose 131.5 to 111.5 Pregelatinised maize starch 7.5 Sodium starch glycollate 4.5 Magnesium stearate 1.5 Compression weight 150.0 ______________________________________

The active ingredient is sieved through a 250 .mu.m sieve and blended with the lactose and pregelatinised maize starch. This mix is granulated by the addition of water. The granules are dried, screened and blended with the sodium starchglycollate and magnesium stearate. The lubricated granules are compressed into tablets using 8.0 mm diameter punches.

______________________________________ 2. injections % w/v ______________________________________ Active ingredient 0.5 Water for injection B.P. to 100.0 ______________________________________

Sodium chloride may be added to adjust the tonicity of the solution and the pH may be adjusted to that of maximum stability using dilute acid or alkali or by the addition of suitable buffer salts.

The solution is prepared, clarified and filled into appropriate sized ampoules sealed by fusion of the glass. The injection is sterilised by heating in an autoclave using one of the acceptable cycles. Alternatively the solution may besterilised by filtration and filled in sterile ampoules under aseptic conditions.

The solution may be packed under an inert atmosphere of nitrogen or other suitable gas.

* * * * *
 
 
  Recently Added Patents
Electrical connector
Data architecture and user interface for plasma processing related software applications
Negative active material for a rechargeable lithium battery, a method of preparing the same, and a rechargeable lithium battery comprising the same
Video processing system and device with encoding and decoding modes and method for use therewith
Case for electronic device
Isolation rings for blocking the interface between package components and the respective molding compound
Scaleable status tracking of multiple assist hardware threads
  Randomly Featured Patents
Process for fabricating an integrated circuit package with reduced mold warping
Method and apparatus for maintaining configuration information in a computing environment
Window vent stop
Biocompatible bonding method and electronics package suitable for implantation
Method and reaction for sustaining high energy reactions
Cap protector
Door frame with integrated exit signage
Compensation method to achieve uniform programming speed of flash memory devices
Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
Etchant and array substrate having copper lines etched by the etchant